Xuanzhu Biopharmaceutical Co (FRA:V59) ROC (Joel Greenblatt) %: -193.58% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V59 Xuanzhu Biopharmaceutical Co Ltd FRA:V59
11 GF Score
Price €1.31
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co ROC (Joel Greenblatt) %?

Xuanzhu Biopharmaceutical Co FRA:V59 +3.00% 11 ROC (Joel Greenblatt) % is -193.58% as of Dec. 2025. GuruFocus rates FRA:V59 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 981 Drug Manufacturers companies, Xuanzhu Biopharmaceutical Co ranks worse than 90.11% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Xuanzhu Biopharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -193.58%.

The historical rank and industry rank for Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:V59' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -289.12   Med: -173.96   Max: -144.3
Current: -165.27

During the past 3 years, Xuanzhu Biopharmaceutical Co's highest ROC (Joel Greenblatt) % was -144.30%. The lowest was -289.12%. And the median was -173.96%.

FRA:V59's ROC (Joel Greenblatt) % is ranked worse than
90.11% of 981 companies
in the Drug Manufacturers industry
Industry Median: 10.75 vs FRA:V59: -165.27

Xuanzhu Biopharmaceutical Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Xuanzhu Biopharmaceutical Co  (FRA:V59) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Xuanzhu Biopharmaceutical Co ROC (Joel Greenblatt) % Related Terms


Xuanzhu Biopharmaceutical Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xuanzhu Biopharmaceutical Co ROC (Joel Greenblatt) % Chart

Xuanzhu Biopharmaceutical Co Annual Data
Trend Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-144.30 -296.37 -162.53

Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % 0.00 -106.39 -517.49 -126.75 -193.58

FRA:V59 vs ZTS: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xuanzhu Biopharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) % falls into.


FRA:V59
11GF Score
Xuanzhu Biopharmaceutical Co Ltd FRA:V59
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xuanzhu Biopharmaceutical Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.485 + 6.471 + 4.656) - (18.118 + 0 + 1.769)
=-8.275

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.944 + 10.491 + 8.652) - (24.578 + 0 + 2.237)
=-5.728

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Xuanzhu Biopharmaceutical Co for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-32.618/( ( (19.668 + max(-8.275, 0)) + (14.032 + max(-5.728, 0)) )/ 2 )
=-32.618/( ( 19.668 + 14.032 )/ 2 )
=-32.618/16.85
=-193.58 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -193.58% mean?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a ROC (Joel Greenblatt) % of -193.58% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. According to the industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #884 out of 981 companies in the Drug Manufacturers industry, placing it in the top 90.1%.
Is Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) % too high?
Xuanzhu Biopharmaceutical Co's current ROC (Joel Greenblatt) % is -193.58%. Based on the distribution chart, Xuanzhu Biopharmaceutical Co ranks #884 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #884 out of 981 companies for ROC (Joel Greenblatt) %. This places Xuanzhu Biopharmaceutical Co in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.75, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current ROC (Joel Greenblatt) % is -193.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a current ROC (Joel Greenblatt) % of -193.58%. The current ROC (Joel Greenblatt) % is -193.58%. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (FRA:V59), the current ROC (Joel Greenblatt) % is -193.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Other Exchanges 02575:Hong Kong
Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for FRA:V59

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price